Cost-effectiveness of hepatitis B vaccine in the Gambia.
Hepatitis B vaccine has been progressively introduced into the Gambian programme of immunization since 1986.
Other African countries are considering introduction but require evidence of cost-effectiveness to justify such a decision.
The cost of the Expanded Programme on Immunization in The Gambia, which includes hepatitis B vaccine, was calculated for 1988.
Estimates of the effects of this programme on the incidence of liver cancer were made, based on the national cancer registry and a case control study of primary liver cancer and hepatitis B, regarding hepatitis B vaccine costs as incremental.
This gave an estimate of the cost of averting a death from liver cancer in the range US$150-200 (assuming a vaccine cost of US$1 per dose).
Mots-clés Pascal : Hépatite virale B, Programme sanitaire, Vaccination, Analyse coût efficacité, Appareil digestif pathologie, Foie pathologie, Virose, Infection, Homme, Couverture, Gambie, Afrique
Mots-clés Pascal anglais : Sanitary program, Vaccination, Cost efficiency analysis, Digestive diseases, Hepatic disease, Viral disease, Infection, Human, Coverage, Gambia, Africa
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 93-0571404
Code Inist : 002B05C02G. Création : 199406.